Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) Director Gary A. Lyons sold 40,000 shares of Travere Therapeutics stock in a transaction on Friday, October 4th. The shares were sold at an average price of $14.73, for a total value of $589,200.00. Following the sale, the director now directly owns 51,000 shares in the company, valued at $751,230. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Travere Therapeutics Price Performance
Shares of NASDAQ:TVTX opened at $15.21 on Wednesday. The company has a market capitalization of $1.16 billion, a PE ratio of -7.24 and a beta of 0.73. The company has a debt-to-equity ratio of 24.96, a quick ratio of 2.99 and a current ratio of 3.04. The stock has a fifty day moving average of $11.31 and a 200-day moving average of $8.78. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $15.61.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. The company had revenue of $54.12 million for the quarter, compared to analysts’ expectations of $49.50 million. As a group, equities analysts anticipate that Travere Therapeutics, Inc. will post -3.95 EPS for the current fiscal year.
Institutional Trading of Travere Therapeutics
Analyst Ratings Changes
A number of research analysts have recently commented on TVTX shares. Citigroup lowered their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, September 27th. Wedbush raised their target price on shares of Travere Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Barclays upped their price target on shares of Travere Therapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 1st. HC Wainwright lowered their price objective on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, September 27th. Finally, JPMorgan Chase & Co. boosted their target price on Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.
View Our Latest Report on TVTX
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Further Reading
- Five stocks we like better than Travere Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is Short Interest? How to Use It
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Earnings Per Share Calculator: How to Calculate EPS
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.